These top ASX 200 stocks could rise 25% to 60%

These shares could be cheap at current levels according to analysts.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points
  • Cochlear is poised for long-term growth driven by increasing global demand for hearing implants, supported by ageing populations and expanding healthcare access, with UBS setting a buy rating and a 25% upside price target of $350.
  • ResMed is capitalising on the vast undiagnosed sleep apnoea market, with innovations and a robust cloud ecosystem creating strong recurring revenue potential, as noted by Macquarie’s 25% upside prediction and $49.20 price target.
  • Xero, a leader in cloud accounting, is positioned for substantial growth with a vast untapped market of small businesses, offering a tremendous 60% upside potential according to Ord Minnett, driven by its expanding global footprint and digital adoption trends.

If you are looking for quality ASX 200 stocks to buy for big potential returns, then read on!

Listed below are three shares that analysts believe can rise very strongly from where they trade today.

After which, they have the potential to compound and build wealth for investors long into the future. Here's why they could be top picks right now:

Two happy and excited friends in euphoria holding a smartphone, after winning in a bet.

Image source: Getty Images

Cochlear Ltd (ASX: COH)

The first ASX 200 stock that could be a top buy is hearing implant leader Cochlear. It appears well position for growth over the long term thanks to rising demand for its devices on the back of ageing populations across the globe and broader access to hearing healthcare.

And with a robust balance sheet and a track record of delivering both earnings and dividend growth, Cochlear could be a blue chip to buy and hold onto for the next decade.

UBS currently rates Cochlear as a buy with a $350.00 price target. This implies potential upside of 25% for investors over the next 12 months.

ResMed Inc. (ASX: RMD)

Another ASX 200 stock to buy and hold could be ResMed. With more than one billion people worldwide estimated to suffer from sleep apnoea, and the vast majority undiagnosed, ResMed has a significant growth runway over the next decade and beyond. The company continues to innovate across masks, devices and software while benefiting from rising awareness and diagnosis rates. Its cloud-connected ecosystem creates sticky customer relationships and high recurring revenue. For investors seeking a defensive growth story backed by secular demand, ResMed could be a top pick.

Macquarie has an outperform rating and $49.20 price target on its shares. This suggests that upside of 25% is possible for investors from current levels.

Xero Ltd (ASX: XRO)

A third ASX 200 stock to consider buying and holding is Xero. It is one of the world's leading cloud accounting platforms and still has a huge global market to chase. With more than 4.5 million subscribers and NZ$2.7 billion in annualised monthly recurring revenue, the company remains in the early stages of penetrating a total addressable market estimated at around 100 million small businesses. As digital adoption accelerates in the UK, North America and Asia, Xero's subscription model and high customer lifetime value create a powerful long-term growth engine.

Ord Minnett is bullish on Xero's outlook. It recently put a buy rating and $200.00 price target on its shares. This implies potential upside of 60% for investors between now and this time next year.

Motley Fool contributor James Mickleboro has positions in Cochlear, ResMed, and Xero. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Cochlear, Macquarie Group, ResMed, and Xero. The Motley Fool Australia has positions in and has recommended Macquarie Group, ResMed, and Xero. The Motley Fool Australia has recommended Cochlear. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Blue Chip Shares

Happy man holding Australian dollar notes, representing dividends.
Blue Chip Shares

2 ASX blue-chip shares offering big dividend yields

These businesses can provide investors with good passive income.

Read more »

Person holding a blue chip.
Blue Chip Shares

2 ASX 200 blue-chip shares worth owning in April 2026

Is this a great time to invest in these shares?

Read more »

Young businesswoman sitting in kitchen and working on laptop.
Blue Chip Shares

Better buy? CSL vs Rio Tinto shares

When two quality shares diverge, I think it is worth taking a closer look.

Read more »

A man looking at his laptop and thinking.
Blue Chip Shares

These ASX blue chips now look too cheap to ignore

These blue chips could be worth a closer look after sharp declines.

Read more »

Young woman thinking with laptop open.
Blue Chip Shares

Why is everyone selling Wesfarmers shares?

It looks like the retail conglomerate fell out of favour with investors this year.

Read more »

Four business people wearing formal business suits and ties walk abreast on a wide paved surface with their long shadows falling on the ground ahead of them.
Blue Chip Shares

How did these ASX blue-chip shares perform in March?

Did these blue-chips beat the market in March?

Read more »

Couple looking at their phone surprised, symbolising a bargain buy.
Blue Chip Shares

Are these ASX blue chips now too cheap to ignore?

Let's see why these shares could be seriously undervalued at current levels.

Read more »

A woman gives two fist pumps with a big smile as she learns of her windfall, sitting at her desk.
Blue Chip Shares

3 reasons to buy Wesfarmers shares today

The retail conglomerate is a no-brainer buy in my book.

Read more »